Does Rallies show Form 4 insider transactions for LENZ?

Yes. Rallies tracks LENZ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LENZ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LENZ. It does not provide personalized investment advice.

LENZ (LENZ Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

LENZ Therapeutics, Inc. Common Stock (LENZ) is a publicly traded Healthcare sector company. As of May 21, 2026, LENZ trades at $7.18 with a market cap of $216.35M and a P/E ratio of -1.97. LENZ moved +8.50% today. Year to date, LENZ is -56.31%; over the trailing twelve months it is -74.94%. Its 52-week range spans $6.61 to $50.40. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces LENZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LENZ stock inside the company?

Recent LENZ insider activity includes George Jeffrey P. bought 5.59K, Schimmelpennink Evert B. bought 28.09K, Chevallard Daniel R. bought 7.50K, Olsson Shawn sold 4.21K, and Olsson Shawn sold 5.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LENZ Key Metrics

Key financial metrics for LENZ
Metric	Value
Price	$7.18
Market Cap	$216.35M
P/E Ratio	-1.97
EPS	$-3.64
Dividend Yield	0.00%
52-Week High	$50.40
52-Week Low	$6.61
Volume	1.22K
Avg Volume	0
Revenue (TTM)	$20.99M
Net Income	$-109.00M
Gross Margin	0.00%

Recent LENZ Insider Trades

George Jeffrey P. bought 5.59K (~$49.89K) on Mar 27, 2026.
Schimmelpennink Evert B. bought 28.09K (~$251.41K) on Mar 27, 2026.
Chevallard Daniel R. bought 7.50K (~$64.28K) on Mar 27, 2026.
Olsson Shawn sold 4.21K (~$108.41K) on Nov 17, 2025.
Olsson Shawn sold 5.79K (~$152.61K) on Nov 17, 2025.

Latest LENZ News

LENZ Therapeutics Reports Strong Q1 Prescription Growth, Launches Phase III Trial — May 12, 2026
LENZ Therapeutics Achieves 19% Prescription Growth, $1.9M Q1 Revenue and Expands Sales Territories — May 11, 2026
LENZ Therapeutics Reports $1.6M Q4 VIZZ Sales, Files EMA MAA — Mar 24, 2026
LENZ Therapeutics Sees Q4 Revenue of $1.89M, EPS -$0.96; 2026 Estimates Cut — Mar 23, 2026
LENZ Therapeutics Earns $56.40 Consensus Price Target from Seven Analysts — Jan 14, 2026

LENZ Analyst Consensus

6 analysts cover LENZ: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.20.

Common questions about LENZ

Who is trading LENZ stock inside the company?: Recent LENZ insider activity includes George Jeffrey P. bought 5.59K, Schimmelpennink Evert B. bought 28.09K, Chevallard Daniel R. bought 7.50K, Olsson Shawn sold 4.21K, and Olsson Shawn sold 5.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LENZ?: Yes. Rallies tracks LENZ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LENZ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LENZ. It does not provide personalized investment advice.